Sector landscape

What we typically see in pharmaceuticals.

Pharmaceutical companies face a uniquely visible ESG profile: energy-intensive facilities, complex global supply chains, water-intensive processes, and a stakeholder base — payers, regulators, patients — increasingly attentive to how medicine is made.

Emerging regulations

  • IFRS S1/S2 and BRSR
  • CSDDD supply-chain due diligence
  • Facility-level emissions regulation

Market expectations

  • Healthcare-system procurement criteria
  • Investor ESG screening
  • Supply-chain transparency

Discuss what's happening in pharmaceuticals with a sector advisor.

A senior advisor will respond within one business day. Confidential, no obligation.